Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL vs AREDIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
Treatment of Paget's disease of bone,Treatment of osteoporosis in postmenopausal women,Prevention of osteoporosis in postmenopausal women,Treatment of glucocorticoid-induced osteoporosis,Off-label: Prevention of bone metastases in some cancers
Hypercalcemia of malignancy,Osteolytic bone metastases of breast cancer,Osteolytic lesions of multiple myeloma,Paget's disease of bone (off-label)
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Not metabolized; excreted unchanged in urine.
Not metabolized; excreted unchanged in urine.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
~24% bound to plasma proteins (primarily albumin).
Approximately 54% bound to plasma proteins, primarily albumin.
Vd: 0.5-1 L/kg, indicating distribution primarily into bone and extracellular fluid.
Steady-state Vd is approximately 0.4-0.6 L/kg, indicating extensive distribution to bone and soft tissues; rapid uptake by bone mineral.
Oral: 0.5-1% under fasting conditions (low due to poor intestinal absorption and high first-pass effect); reduced by 60-90% with food or calcium-containing beverages.
Intravenous: 100% (only route). Oral bioavailability is <1% and clinically irrelevant; no oral formulation available.
Contraindicated if Cr Cl <30 m L/min. If Cr Cl 30-49 m L/min, no adjustment needed. If Cr Cl <30 m L/min, do not use.
For Cr Cl >50 m L/min: no adjustment; Cr Cl 30-50 m L/min: reduce dose to 60 mg; Cr Cl <30 m L/min: not recommended (no data).
No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use caution.
No specific adjustment recommended; use caution in severe hepatic impairment due to limited data.
Safety and efficacy not established in pediatric patients. Not recommended for use in children.
Safety and efficacy not established for pediatric patients.
No dose adjustment based on age alone. Monitor renal function. Ensure adequate calcium and vitamin D intake. Same dosing as adults.
No specific dose adjustment required; monitor renal function and fluid status carefully owing to age-related decreased glomerular filtration rate.
None.
None
Hypocalcemia must be corrected before therapy,Esophageal irritation and potential for esophageal cancer,Renal impairment (creatinine clearance <30 m L/min) requires dose adjustment or avoidance,Osteonecrosis of the jaw (usually with cancer treatments),Atypical femur fractures with long-term use,Musculoskeletal pain
Renal impairment,Osteonecrosis of the jaw,Hypocalcemia,Severe musculoskeletal pain,Atypical femur fractures
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Hypersensitivity to risedronate or any component
Hypersensitivity to pamidronate or other bisphosphonates,Hypocalcemia
Calcium, magnesium, iron, and aluminum (e.g., antacids) bind risedronate and reduce absorption. Separate by at least 30 minutes after taking risedronate. Avoid mineral water, dairy products, and calcium-fortified juices within 30 minutes of dosing.
No specific food interactions. Avoid excessive intake of calcium or vitamin D supplements unless prescribed. Maintain adequate hydration.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for skeletal effects; second and third trimesters: risk of fetal hypocalcemia and skeletal retardation. Discontinue if pregnancy occurs.
Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fetal weight. There is no adequate and well-controlled study in pregnant women; however, postmarketing reports indicate fetal skeletal abnormalities (e.g., shortened long bones) when bisphosphonates are used during pregnancy. First trimester exposure may be associated with neonatal hypocalcemia and skeletal effects. Second and third trimester exposure may increase risk for fetal skeletal mineralization defects.
Unknown if excreted in human milk. M/P ratio not established. Caution advised; consider alternative treatments during breastfeeding.
It is not known whether pamidronate is excreted in human milk. The M/P ratio is unknown. Due to potential for skeletal toxicity and hypocalcemia in the nursing infant, advise women not to breastfeed during treatment and for a period after the last dose (at least 1-2 weeks based on half-life).
No specific pharmacokinetic data during pregnancy. Dose adjustments not routinely recommended; consider discontinuation due to potential fetal risks.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic data. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce drug exposure; nevertheless, because risk outweighs benefit, use is contraindicated. If used despite risk, consider monitoring serum calcium and adjusting dose based on serum calcium response and renal function, but no standard pharmacokinetic-based dosing exists.
Actonel (risedronate) is a bisphosphonate for osteoporosis and Paget's disease. Administer on an empty stomach with plain water (not mineral water) at least 30 minutes before the first food, beverage, or other medication. Avoid in Cr Cl <30 m L/min. Monitor for hypocalcemia before treatment. Counsel on atypical femur fractures and osteonecrosis of the jaw (ONJ), especially with dental procedures.
Monitor serum calcium, phosphate, and magnesium regularly. Aredia (pamidronate) is contraindicated in severe renal impairment (Cr Cl <30 m L/min). Administer as a slow IV infusion (over at least 2 hours for 90 mg dose; 4 hours for metastatic bone disease) to reduce risk of nephrotoxicity. Hydrate adequately before infusion. Assess for osteonecrosis of the jaw (ONJ) and perform dental exam before therapy. Not recommended in pregnancy and lactation.
Take Actonel first thing in the morning with a full glass of plain water (6-8 oz) at least 30 minutes before any food, drink, or other medicine.,Do not lie down for at least 30 minutes after taking to reduce risk of esophageal irritation.,Avoid mineral water, coffee, tea, juice, or calcium-rich beverages as they can reduce absorption.,Report severe bone, joint, or muscle pain; jaw pain or numbness; or signs of hypocalcemia (muscle cramps, tingling).,Maintain adequate calcium and vitamin D intake as directed by your doctor.,If you miss a dose, skip it and resume next morning; do not take two doses on the same day.
You must have regular blood tests to monitor calcium, phosphate, and magnesium levels.,Report any bone pain, jaw pain, or swelling in your mouth immediately.,Maintain good oral hygiene and undergo a dental check-up before starting treatment.,Drink plenty of fluids before and after each infusion.,This drug is not safe during pregnancy; use effective contraception if applicable.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL vs AREDIA, answered by our medical review team.
ACTONEL is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.. AREDIA is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL and AREDIA depend on the specific clinical indication. These are both Bisphosphonate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL is: 35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.. The standard adult dose of AREDIA is: 90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL and AREDIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. Risk cannot be ruled out; use only. AREDIA is classified as Category C. Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.